Increasing role of fondaparinux in patients with acute coronary syndromes Review article
Article Sidebar
Published:
Dec 31, 2008
Keywords:
fondaparinux, enoxaparin, acute coronary syndromes (ACS), percutaneous coronary intervention (PCI), renal failure
Main Article Content
Abstract
Haemmorhagic complications are one of the most important limitations of anticoagulant treatment in acute coronary syndromes (ACS). Fondaparinux is a novel agent similary efficient as heparin, but rarely causes such complications. The paper refers to three fundamental trials with fondaparinux which confirm safety and efficacy of the drug in different group patients with ACS. Results of these trials incorporated the drug to latest ACS NSTEMI guidelines.
Article Details
How to Cite
Janiszewski , M., & Chmielewski , M. (2008). Increasing role of fondaparinux in patients with acute coronary syndromes. Medycyna Faktow (J EBM), 1(1(1), 62-67. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/1809
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S., Mehta S.R., Chrolavicius S., Afzal R., Pogue J., Granger C.B., Budaj A., Peters R.J., Bassand J.P., Wallentin L., Joyner C., Fox K.A.: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 2006 Apr 6; 354(14): 1464-76.
2. Mehta S.R., Granger C.B., Eikelboom J.W., Bassand J.P., Wallentin L., Faxon D.P., Peters R.J., Budaj A., Afzal R., Chrolavicius S., Fox K.A., Yusuf S.: Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J. Am. Coll. Cardiol. 2007 Oct 30; 50(18): 1742-51.
3. Fox K.A., Bassand J.P., Mehta S.R., Wallentin L., Theroux P., Piegas L.S., Valentin V., Moccetti T., Chrolavicius S., Afzal R., Yusuf S. (OASIS 5 Investigators): Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non STsegment elevation acute coronary syndromes. Ann. Intern. Med. 2007 Sep 4; 147(5): 304-10.
4. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand J.P., Hamm C.W., Ardissino D., Boersma E., Budaj A., Fernández-Avilés F., Fox K.A., Hasdai D., Ohman E.M., Wallentin L., Wijns W.: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 2007 Jul; 28(13): 1598-660.
2. Mehta S.R., Granger C.B., Eikelboom J.W., Bassand J.P., Wallentin L., Faxon D.P., Peters R.J., Budaj A., Afzal R., Chrolavicius S., Fox K.A., Yusuf S.: Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J. Am. Coll. Cardiol. 2007 Oct 30; 50(18): 1742-51.
3. Fox K.A., Bassand J.P., Mehta S.R., Wallentin L., Theroux P., Piegas L.S., Valentin V., Moccetti T., Chrolavicius S., Afzal R., Yusuf S. (OASIS 5 Investigators): Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non STsegment elevation acute coronary syndromes. Ann. Intern. Med. 2007 Sep 4; 147(5): 304-10.
4. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand J.P., Hamm C.W., Ardissino D., Boersma E., Budaj A., Fernández-Avilés F., Fox K.A., Hasdai D., Ohman E.M., Wallentin L., Wijns W.: Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 2007 Jul; 28(13): 1598-660.